Vetpa, UAB

Company age: 29 y. 2 mo.

Update

Company overview

Company name Vetpa, UAB
Company code 173212877
Registered address Rokiškis, Respublikos g. 111, LT-42135
Registration date 1997-07-01 Company age: 29 y. 2 mo.
Phone Phone
Email Not disclosed (personal)
Website None
Company manager For registered members only Log in
Revenue (2025) 26,011 € -27% History
Profit (2025) -4,135 € History
Share capital 2,896 €
Number of employees 0 History
Managed vehicles 0
Current SODRA debt No debt Read more
Days of debt to SODRA per year 0 days
Current VMI debt No debt Read more
Financial statements All submitted
Legal form Private Limited Liability Company
NACE activity Retail sale of pharmaceutical products
Ownership form Private without foreign capital

Download a detailed company report

Make confident decisions with all the information about Vetpa, UAB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.

19.99 € + PVM Get report

Description

This description was generated by artificial intelligence.
Vetpa, UAB (company code 173212877) is an operational private limited liability company registered in 1997. It is classified as a private, privately owned Lithuanian non-financial company, with governance described as CEO only. The company is based in Rokiškis, Respublikos g. 111, Rokiškio r. sav., Panevežio apskr. Its main activity is EVRK G.47.73.00, retail sale of pharmaceutical products. The company is classified as micro-sized and has share capital of €2.9K.

Financially, Vetpa, UAB remained loss-making in the latest reported years. Revenue increased from €32.1K in 2023 to €35.5K in 2024, then declined to €26.0K in 2025. Net profit was negative in all three years, moving from -€1.4K in 2023 to -€720 in 2024 and widening to -€4.1K in 2025. The 2025 profit margin was -15.9%. Equity stayed negative, at -€4.5K in 2023, -€5.3K in 2024 and -€9.4K in 2025, while liabilities increased to €9.4K in 2025. The company had an average of 2 employees in each of 2023, 2024 and 2025.